Skyepharma PLC announces Board Appointment


            Appointment of New Non-Executive Director

LONDON, UK, 15 May, 2009 - SkyePharma PLC (LSE: SKP) today announces
that it will appoint a new Non-Executive Director, Dr Thomas Werner, to
the Board with effect from 16 May 2009.

Dr Werner, 52, is a senior-level pharmaceutical executive with
over 26 years experience in the pharmaceutical industry, most recently
as Managing Director and Senior Vice-President of GlaxoSmithKline
Germany. Prior to that, he held senior positions at GlaxoWellcome
Germany, Bristol-Myers Squibb Germany and Convatec Germany, (a medical
devices subsidiary of Bristol Myers Squibb).  Dr Werner sits on the
Board of Trustees of both the Paul Ehrlich Association and the Robert
Koch Foundation.

No disclosures are required under section 9.6.13 of the Listing Rules.

As previously announced Dr Argeris (Jerry) Karabelas will stand down
from the Board at the conclusion of the Annual General Meeting taking
place later today.

Jeremy Scudamore, Non-Executive Chairman of SkyePharma, said:  "On
behalf of the Board and staff, I would like to reiterate my thanks to
Jerry for the tremendous contribution he has made to the Company over
the past eight years and to welcome Thomas to the Board of SkyePharma.
His experience as a senior international manager in the pharmaceutical
industry will enable him to be of significant value to SkyePharma as it
moves forward."

For further information please contact:

SkyePharma PLC      Ken Cunningham  +44 20 7491 1777
                    Peter Grant

Financial Dynamics  Jonathan Birt   +44 20 7831 3113
                    Susan Quigley


About SkyePharma PLC

Using its proprietary drug delivery technologies, SkyePharma develops
new formulations of existing products to provide a clinical advantage
and life-cycle extension. The Group has twelve approved products in the
areas of oral, inhalation and topical delivery. The Group's products
are marketed throughout the world by leading pharmaceutical companies.
For more information, visit www.skyepharma.com.


                    This information is provided by RNS
          The company news service from the London Stock Exchange

END

Contacts: RNS Customer Services 0044-207797-4400 Email Contact http://www.rns.com

Skye Bioscience (NASDAQ:SKYE)
과거 데이터 주식 차트
부터 5월(5) 2024 으로 6월(6) 2024